|Bid||0.4040 x 1200|
|Ask||0.4097 x 1300|
|Day's Range||0.4000 - 0.5001|
|52 Week Range||0.4000 - 21.3000|
|Beta (5Y Monthly)||-0.18|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 09, 2022 - Aug 15, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||26.75|
Evofem Biosciences, Inc. ( NASDAQ:EVFM ) shareholders should be happy to see the share price up 15% in the last month...
Evofem Biosciences, Inc. (NASDAQ: EVFM) and Orion Biotechnology Canada Ltd. today announced that they have entered into a collaboration agreement to evaluate the compatibility and stability of Orion's novel CCR5 antagonist, OB-002, in Evofem's Phexxi® (lactic acid, citric acid and potassium bitartrate) vaginal gel with the goal of developing a Multipurpose Prevention Technology (MPT) product candidate for indications including the prevention of HIV in women.
Every investor on earth makes bad calls sometimes. But you want to avoid the really big losses like the plague. So...